These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 25319391)

  • 1. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
    Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R
    Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
    Gritsina G; Xiao F; O'Brien SW; Gabbasov R; Maglaty MA; Xu RH; Thapa RJ; Zhou Y; Nicolas E; Litwin S; Balachandran S; Sigal LJ; Huszar D; Connolly DC
    Mol Cancer Ther; 2015 Apr; 14(4):1035-47. PubMed ID: 25646015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
    Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
    Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.
    Saini U; Naidu S; ElNaggar AC; Bid HK; Wallbillich JJ; Bixel K; Bolyard C; Suarez AA; Kaur B; Kuppusamy P; Hays J; Goodfellow PJ; Cohn DE; Selvendiran K
    Oncogene; 2017 Jan; 36(2):168-181. PubMed ID: 27292260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
    Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
    BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling.
    Wang H; Hou W; Perera A; Bettler C; Beach JR; Ding X; Li J; Denning MF; Dhanarajan A; Cotler SJ; Joyce C; Yin J; Ahmed F; Roberts LR; Qiu W
    Cell Rep; 2021 Feb; 34(8):108765. PubMed ID: 33626345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway.
    Liao J; Xu T; Zheng JX; Lin JM; Cai QY; Yu DB; Peng J
    Int J Mol Med; 2013 Jul; 32(1):79-84. PubMed ID: 23613111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
    Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
    Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.
    Shien K; Papadimitrakopoulou VA; Ruder D; Behrens C; Shen L; Kalhor N; Song J; Lee JJ; Wang J; Tang X; Herbst RS; Toyooka S; Girard L; Minna JD; Kurie JM; Wistuba II; Izzo JG
    Mol Cancer Ther; 2017 Oct; 16(10):2234-2245. PubMed ID: 28729401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
    McLean K; Tan L; Bolland DE; Coffman LG; Peterson LF; Talpaz M; Neamati N; Buckanovich RJ
    Oncogene; 2019 Feb; 38(9):1576-1584. PubMed ID: 30305729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
    Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
    Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo.
    Zhang X; Liu P; Zhang B; Mao H; Shen L; Ma Y
    Int J Mol Med; 2013 Sep; 32(3):623-8. PubMed ID: 23828376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination.
    Yasuda T; Koiwa M; Yonemura A; Miyake K; Kariya R; Kubota S; Yokomizo-Nakano T; Yasuda-Yoshihara N; Uchihara T; Itoyama R; Bu L; Fu L; Arima K; Izumi D; Iwagami S; Eto K; Iwatsuki M; Baba Y; Yoshida N; Ohguchi H; Okada S; Matsusaki K; Sashida G; Takahashi A; Tan P; Baba H; Ishimoto T
    Cell Rep; 2021 Feb; 34(8):108779. PubMed ID: 33626356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.
    Mehner C; Miller E; Hockla A; Coban M; Weroha SJ; Radisky DC; Radisky ES
    Oncogene; 2020 Oct; 39(42):6606-6618. PubMed ID: 32929152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.
    Subramaniam A; Shanmugam MK; Ong TH; Li F; Perumal E; Chen L; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Hui KM; Sethi G
    Br J Pharmacol; 2013 Oct; 170(4):807-21. PubMed ID: 23848338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Berberine suppresses bladder cancer cell proliferation by inhibiting JAK1-STAT3 signaling via upregulation of miR-17-5p.
    Xia Y; Chen S; Cui J; Wang Y; Liu X; Shen Y; Gong L; Jiang X; Wang W; Zhu Y; Sun S; Li J; Zou Y; Shi B
    Biochem Pharmacol; 2021 Jun; 188():114575. PubMed ID: 33887260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
    Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling.
    Huang Z; Zhou W; Li Y; Cao M; Wang T; Ma Y; Guo Q; Wang X; Zhang C; Zhang C; Shen W; Liu Y; Chen Y; Zheng J; Yang S; Fan Y; Xiang R
    Theranostics; 2018; 8(18):4995-5011. PubMed ID: 30429882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adipokine Apelin/APJ Pathway Promotes Peritoneal Dissemination of Ovarian Cancer Cells by Regulating Lipid Metabolism.
    Dogra S; Neelakantan D; Patel MM; Griesel B; Olson A; Woo S
    Mol Cancer Res; 2021 Sep; 19(9):1534-1545. PubMed ID: 34172534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.